PsiOxus Lands $34M to Create 4 Years of Runway for ColoAd1

By Nuala MoranStaff Writer

Wednesday, August 8, 2012

LONDON – PsiOxus Therapeutics Ltd. has raised £22 million (US$34 million) in its Series B round to finance the first clinical trial of its systemically acting oncolytic virus ColoAd1, in a 132-patient colorectal cancer study that will get under way in September.